|
US20070244120A1
(en)
*
|
2000-08-18 |
2007-10-18 |
Jacques Dumas |
Inhibition of raf kinase using substituted heterocyclic ureas
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
ATE538794T1
(de)
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
CN100379734C
(zh)
|
1999-12-24 |
2008-04-09 |
阿文蒂斯药物有限公司 |
氮杂吲哚类化合物
|
|
WO2001057034A1
(en)
|
2000-02-07 |
2001-08-09 |
Bristol-Myers Squibb Co. |
3-aminopyrazole inhibitors of cyclin dependent kinases
|
|
AU2001253540A1
(en)
|
2000-04-25 |
2001-11-07 |
Bristol-Myers Squibb Company |
Use of 5-thio-, sulfinyl- and sulfonylpyrazolo(3,4-b)-pyridines as cyclin dependent kinase inhibitors
|
|
EP1313710A1
(en)
*
|
2000-08-31 |
2003-05-28 |
Pfizer Products Inc. |
Pyrazole derivatives and their use as protein kinase inhibitors
|
|
AU2002215053A1
(en)
*
|
2000-11-27 |
2002-06-24 |
Pharmacia Italia S.P.A. |
Phenylacetamido- pyrazole derivatives and their use as antitumor agents
|
|
GB0115109D0
(en)
*
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
EP1769795B1
(en)
*
|
2001-12-03 |
2013-07-24 |
Bayer HealthCare LLC |
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
|
|
US20050113283A1
(en)
*
|
2002-01-18 |
2005-05-26 |
David Solow-Cordero |
Methods of treating conditions associated with an EDG-4 receptor
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
KR20030071029A
(ko)
*
|
2002-02-27 |
2003-09-03 |
주식회사 팜제니아 |
항암제 및 방사선 치료 증진제로서 유용한 조성물
|
|
US20030225089A1
(en)
*
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
|
DE10221052A1
(de)
*
|
2002-05-10 |
2003-12-04 |
Transmit Technologietransfer |
Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
|
|
WO2003097610A1
(en)
*
|
2002-05-17 |
2003-11-27 |
Pharmacia Italia S.P.A. |
Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
CA2493458A1
(en)
*
|
2002-07-24 |
2004-01-29 |
Ptc Therapeutics, Inc. |
Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
|
|
DE60328202D1
(de)
*
|
2002-09-05 |
2009-08-13 |
Neurosearch As |
Diarylharnstoffderivate und deren verwendung als chloridkanalblocker
|
|
JP2006504725A
(ja)
|
2002-10-09 |
2006-02-09 |
ファイザー・プロダクツ・インク |
神経変性障害治療用ピラゾール化合物
|
|
UA81790C2
(uk)
|
2002-12-19 |
2008-02-11 |
Фармация Италия С.П.А. |
Заміщені піролопіразольні похідні як інгібітори кінази
|
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
|
GB0305426D0
(en)
*
|
2003-03-08 |
2003-04-16 |
Glaxo Group Ltd |
Novel compounds
|
|
EP1626714B1
(en)
|
2003-05-20 |
2007-07-04 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas for diseases mediated by pdgfr
|
|
KR101084871B1
(ko)
|
2003-05-22 |
2011-11-21 |
네르비아노 메디칼 사이언시스 에스.알.엘. |
피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도
|
|
US7141568B2
(en)
|
2003-07-09 |
2006-11-28 |
Pfizer Italia S.R.L. |
Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
TW200526204A
(en)
|
2004-02-03 |
2005-08-16 |
Pharmacia Italia Spa |
1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
|
|
US7244757B2
(en)
|
2004-04-01 |
2007-07-17 |
Pfizer Inc |
Pyrazole-amine compounds for the treatment of neurodegenerative disorders
|
|
EP1609789A1
(en)
*
|
2004-06-23 |
2005-12-28 |
Eli Lilly And Company |
Ureido-pyrazole derivatives and their use as kinase inhibitors
|
|
HRP20080608T3
(hr)
*
|
2004-08-12 |
2008-12-31 |
Pfizer Inc. |
Triazolopiridinilsulfanilni derivati kao inhibitori p38 map kinaze
|
|
DK1836179T3
(en)
|
2004-12-30 |
2015-05-26 |
Janssen Pharmaceutica Nv |
PIPERIDINE AND PIPERAZINE-1-CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FAT ACID AMIDE HYDRALASE (FAAH) FOR THE TREATMENT OF ANCIENT, PAIN AND OTHER CONDITIONS
|
|
US20060183758A1
(en)
*
|
2005-02-17 |
2006-08-17 |
Cb Research And Development, Inc. |
Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
|
|
US7429800B2
(en)
*
|
2005-06-30 |
2008-09-30 |
Sabic Innovative Plastics Ip B.V. |
Molding composition and method, and molded article
|
|
US7943654B2
(en)
|
2005-07-19 |
2011-05-17 |
Nerviano Medical Sciences S.R.L. |
1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
|
|
AR059826A1
(es)
*
|
2006-03-13 |
2008-04-30 |
Univ California |
Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
|
|
JP2009535388A
(ja)
*
|
2006-05-03 |
2009-10-01 |
アストラゼネカ アクチボラグ |
ピラゾール誘導体、及びそのｐｉ３ｋ阻害薬としての使用
|
|
KR20090071662A
(ko)
*
|
2006-10-21 |
2009-07-01 |
애보트 게엠베하 운트 콤파니 카게 |
헤테로사이클릭 화합물 및 글리코겐 신타제 키나제 3 억제제로서의 이의 용도
|
|
CL2008000119A1
(es)
|
2007-01-16 |
2008-05-16 |
Wyeth Corp |
Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
|
|
WO2008128986A1
(en)
*
|
2007-04-18 |
2008-10-30 |
Probiodrug Ag |
Urea derivatives as glutaminyl cyclase inhibitors
|
|
RU2009148304A
(ru)
*
|
2007-05-25 |
2011-06-27 |
Янссен Фармацевтика Н.В. (Be) |
Модуляторы гидролазы амидов жирных кислот на основе гетероарилзамещенной мочевины
|
|
EP2163541A1
(en)
*
|
2008-09-12 |
2010-03-17 |
Bayer Schering Pharma Aktiengesellschaft |
Piperazine derivatives for binding and imaging amyloid plaques and their use
|
|
WO2010051127A2
(en)
*
|
2008-10-01 |
2010-05-06 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
|
WO2010068452A1
(en)
*
|
2008-11-25 |
2010-06-17 |
Janssen Pharmaceutica Nv |
Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
|
|
US8461159B2
(en)
|
2008-11-25 |
2013-06-11 |
Jannsen Pharmaceutica BV |
Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
|
|
AU2010248886A1
(en)
|
2009-05-13 |
2011-12-01 |
The University Of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
WO2010141817A1
(en)
|
2009-06-05 |
2010-12-09 |
Janssen Pharmaceutica Nv |
Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
|
|
US8901111B2
(en)
|
2009-06-05 |
2014-12-02 |
Janssen Pharmaceutica Nv |
Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
|
|
EP2528604B1
(en)
|
2010-01-29 |
2017-11-22 |
The Regents of the University of California |
Acyl piperidine inhibitors of soluble epoxide hydrolase
|
|
UA108233C2
(uk)
|
2010-05-03 |
2015-04-10 |
|
Модулятори активності гідролази амідів жирних кислот
|
|
EP2588443A2
(en)
*
|
2010-07-02 |
2013-05-08 |
Ventana Medical Systems, Inc. |
Hapten conjugates for target detection
|
|
MX2013002011A
(es)
*
|
2010-08-20 |
2013-03-25 |
Gruenenthal Gmbh |
Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor vainiloide.
|
|
US9266855B2
(en)
|
2010-09-27 |
2016-02-23 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
|
JP5980225B2
(ja)
|
2010-12-17 |
2016-08-31 |
ナーヴィアノ メディカル サイエンシズ エス．アール．エル． |
キナーゼ阻害剤としての置換ピラゾロ−キナゾリン誘導体
|
|
US9090592B2
(en)
|
2010-12-30 |
2015-07-28 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
|
UA114711C2
(uk)
|
2011-05-13 |
2017-07-25 |
Еррей Біофарма Інк. |
Сполуки піролідинілсечовини й піролідинілтіосечовини як інгібітори кінази trka
|
|
AR087701A1
(es)
*
|
2011-08-31 |
2014-04-09 |
Japan Tobacco Inc |
Derivados de pirazol con actividad inhibidora de sglt1
|
|
WO2014078331A1
(en)
*
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
HRP20161613T1
(hr)
|
2012-11-13 |
2017-01-13 |
Array Biopharma, Inc. |
Tvari bicikličke ureje, tioureje, gvanidina i cijanogvanidina korisne za liječenje boli
|
|
US9981959B2
(en)
|
2012-11-13 |
2018-05-29 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
WO2014078328A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
WO2014078378A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
US9822118B2
(en)
|
2012-11-13 |
2017-11-21 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
US9809578B2
(en)
|
2012-11-13 |
2017-11-07 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
|
|
EP2922844B1
(en)
|
2012-11-13 |
2018-01-10 |
Array Biopharma, Inc. |
N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
US9790178B2
(en)
|
2012-11-13 |
2017-10-17 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
US9790210B2
(en)
|
2012-11-13 |
2017-10-17 |
Array Biopharma Inc. |
N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
HK1222766A1
(zh)
|
2013-03-15 |
2017-07-14 |
G1治疗公司 |
高效的抗赘生剂和抗增生剂
|
|
RS59790B1
(sr)
|
2013-03-15 |
2020-02-28 |
G1 Therapeutics Inc |
Privremena zaštita normalnih ćelija tokom hemoterapije
|
|
US20150297606A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
|
|
RU2719489C2
(ru)
|
2014-05-15 |
2020-04-17 |
Эррэй Биофарма Инк. |
1-((3S,4R)-4-(3-ФТОРФЕНИЛ)-1-(2-МЕТОКСИЭТИЛ)ПИРРОЛИДИН-3-ИЛ)-3-(4-МЕТИЛ-3-(2-МЕТИЛПИРИМИДИН-5-ИЛ)-1-ФЕНИЛ-1Н-ПИРАЗОЛ-5-ИЛ)МОЧЕВИНА В КАЧЕСТВЕ ИНГИБИТОРА TrkA КИНАЗЫ
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
WO2020252240A1
(en)
*
|
2019-06-14 |
2020-12-17 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
TW202229268A
(zh)
*
|
2020-12-22 |
2022-08-01 |
大陸商上海拓界生物醫藥科技有限公司 |
Ｃｄｋ２抑制劑及其製備方法
|
|
US12152018B2
(en)
|
2021-01-08 |
2024-11-26 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with STING activity
|